The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
U.S. FDA to decide whether to authorize a booster dose in the coming days
The applicants will only have to get their Good Manufacturing Practices certification validated every five years to retain their licence
This opens up a huge market for the company’s Magnezis implants in India
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
This facility will integrate with existing Max hospitals and create a 2,300-bed contiguous medical hub spread over 23 acres. The first phase is to be ready by 2024
Advances deployment of mRNA technology across vaccines and therapeutics development
It works as an adjunct to standard care based on robust clinical trials
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Presently, IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum
Subscribe To Our Newsletter & Stay Updated
